Neurogene Inc. 4

Keith Woods received a stock option award for 15,400 shares of Neurogene Inc. common stock at a $32.30 exercise price, vesting monthly through January 16, 2027.

On January 16, 2024, Keith Woods, an insider of Neurogene Inc., was granted a stock option to purchase 15,400 shares of the company’s common stock at an exercise price of $32.30 per share, with the option vesting in equal monthly installments through January 16, 2027, contingent on his continued service. This Form 4 is an amendment and refiling of the original January 18, 2024 submission to correct the reporting person’s CIK number, and it reports no immediate change in common stock ownership as the transaction reflects an option award rather than an exercised purchase. The estimated face value of the option grant is approximately $497,420, and following this award he is reported as beneficially owning 15,400 shares of common stock on a derivative basis. Given the nature of the transaction as routine equity compensation vesting over time, it is notable but not unusually aggressive from a corporate governance perspective.

Filing Facts

CIK

1404644

Ticker

NGNE

Form

4

Source Type

sec

Accession

0001996804-26-000011

Alert Tier

5